U.S. Department of Health and Human Services. FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. Available online at http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm. Accessed October 19, 2016.
American Association for the Study of Liver Disease and Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available online at http://www.hcvguidelines.org. Accessed October 18, 2016.
European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. Journal of Hepatology. Article in press 2016: http://dx.doi.org/10.1016/j. jhep.2016.09.001.
Mayo Clinic Staff. Hepatitis C Treatment. Available online at http://www.mayoclinic.org/diseases-conditions/hepatitis-c/diagnosis-treatment/treatment/txc-20207409. Accessed October 18, 2016.
DeMonte A, Courjon J, Anty R, et al. Direct-acting Antiviral Treatment in Adults Infected with Hepatitis C Virus: Reactivation of Hepatitis B Virus Coinfection as a Further Challenge. Journal of Clinical Virology. 2016;78:27-30.
Liu C. Treatment of Patients With Dual Hepatitis C Virus and Hepatitis B Virus Infection: Resolved and Unresolved Issues. Journal of Gastroenterology and Hepatology. 2014;29(1):26-30.